{"id":159726,"name":"AMIVAS, LLC","slug":"amivas-llc","state":"DE","country":"United States of America","description":"Pharmaceutical company","totalSpending":100000,"filings":26,"yearlySpending":[{"year":2019,"income":40000},{"year":2020,"income":60000},{"year":2021,"income":0},{"year":2022,"income":0},{"year":2023,"income":0}],"issues":[{"code":"VET","display":"Veterans"},{"code":"HOM","display":"Homeland Security"},{"code":"MED","display":"Medical/Disease Research/Clinical Labs"},{"code":"HCR","display":"Health Issues"}],"firms":["BUCHANAN INGERSOLL & ROONEY PC"],"lobbyists":["TIMOTHY COSTA","MICHAEL STRAZZELLA","ELIZABETH WESTBROOK","MICHAEL WESTBROOK"],"govEntities":["Food & Drug Administration (FDA)","HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Federal government relations service, strategy development and implementation relating to replacements for quinidine gluconate for treating severe malaria in the US.","Federal government relations service, strategy development and implementation relating to replacements for quinidine gluconate for treating severe malaria in the US.","Federal government relations service, strategy development and implementation relating to replacements for quinidine gluconate for treating severe malaria in the US.","Federal government relations service, strategy development and implementation relating to replacements for quinidine gluconate for treating severe malaria in the US.","Federal government relations service, strategy development and implementation relating to replacements for quinidine gluconate for treating severe malaria in the US."]}